African health authorities and Maryland-based global life sciences company, Emergent BioSolutions, recently announced that US approved smallpox drug, brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa’ (MOSA).